Isleworth Healthcare Acquisition Corp. neCytovia Holdings, Inc. nhasi vazivisa kuti vapinda muchibvumirano chechokwadi chemubatanidzwa webhizinesi. Pakupera kwemubatanidzwa uyu, Isleworth ichatumidzwa zita rekuti Cytovia Therapeutics, Inc. (iyo "kambani yakasanganiswa") uye masheya ayo akajairika uye waranti inotarisirwa kuramba yakanyorwa paNASDAQ pasi peticker zviratidzo INKC uye INKCW, zvichiteerana.
Kambani yakasanganiswa ichaenderera mberi nekushanda kweCytovia uye kuramba yakatarisana nekugadzira nekugadzira inowirirana NK cell uye NK engager antibody mapuratifomu.
Kambani yakabatanidzwa ichatungamirirwa naDr. Daniel Teper, Co-Founder, Sachigaro, uye Chief Executive Officer weCytovia.
“Tinotenda nerutsigiro rwakasimba kubva kune vemabhizimisi vatsva uye varipo uye nechikwata chevemabhizimusi vane ruzivo rwokuzviwanira kuIsleworth. Tinotarisira kuti kutengeserana uku kukurumidze kuitwa kwechiratidzo cheCytovia chekusimudzira NK therapeutics kusvika pamushonga wegomarara” akadaro Dr. Teper. "Tinokurudzirwa nedata yedu yepreclinical ichangobva kuratidzwa kuAACR, iyo inotsigira kufambisira mberi kwePSC-yakatorwa NK masero (iNK) uye Flex-NK™ cell engagers pakurapa Hepatocellular Carcinoma."
Bob Whitehead, CEO weIsleworth, akati: "Isleworth yakaongorora makambani mazhinji esainzi yehupenyu uye yakafadzwa zvakanyanya netarenda uye tekinoroji zvakaunganidzwa naCytovia. Isu tinotenda Cytovia ndeimwe yeakanyanya kufambira mberi, makambani ekurapa maseru ane chekuita nekuvandudzwa kwemishonga mitsva yegomarara. Kurapa kwemasero mu oncology kwakatounza tariro kumamiriyoni. Maitiro aCytovia anogona kuita kuti nzira dzakafanana dzive nyore 'kunze-pasherufu' uye kukwanisika. ”
Cytovia's Therapeutic Nzira
Cytovia ine chinangwa chekusimudzira kuwana kwemurwere kune shanduko sero therapies uye immunotherapies, kugadzirisa akati wandei ezvakanyanya kunetsa zvisingaite zvinodiwa pakurapa mune oncology.
Iyo kambani inotarisa pakushandisa iyo innate immune system nekugadzira inopindirana uye inovhiringidza NK-cell uye NK-engager antibody mapuratifomu. Kunyanya, Cytovia iri kugadzira marudzi matatu eNK masero: asina kuvharwa eNK masero, TALEN® gene-edited eNK masero ane basa rakagadziridzwa uye kutsungirira, uye TALEN® gene-edited iNK masero ane chimeric antigen receptors (CAR-iNKs) kuvandudza bundu-chaiyo. kunanga. Yechipiri inopindirana tekinoroji yekona yekona ndeye quadrivalent multispecific antibody chikuva chakagadzirirwa kubata NK maseru nekunanga NKp46 activating receptor vachishandisa proprietary Flex-NK™ tekinoroji.
Aya maviri matekinoroji mapuratifomu ari kushandiswa kugadzira marapirwo evarwere vane Hepatocellular Carcinoma (HCC) nemamota akasimba. Zvidzidzo zvekiriniki zvinotarisirwa kutanga mukupera kwa2022.
Inotungamirwa muAventura, FL, Cytovia inoshandisa marabhoritari eR&D muNatick, MA uye cGMP masero ekugadzira masero muPuerto Rico uye ine kudyidzana kwesainzi neCellectis, CytoImmune Therapeutics, iyo Hebrew University yeJerusarema, INSERM, iyo New York Stem Cell Foundation, iyo National. Cancer Institute, uye Yunivhesiti yeCalifornia San Francisco (UCSF). Cytovia Therapeutics ichangobva kuumba CytoLynx Therapeutics, mubatanidzwa wakanangana nekutsvaga nekusimudzira, kugadzira, uye kushambadzira zviitiko muGreater China nekumhiri.
Cytovia Pipeline
Cytovia ndiyo yekutanga immune-oncology kambani ine kugona kusanganisa gene rakagadziridzwa iPSC-yakatorwa NK Cell uye Flex-NK™ cell engager antibody mapuratifomu kusimudzira chizvarwa chinotevera che immunotherapies kune ese ari maviri ehematological uye akasimba mamota.
Cytovia's portfolio inosanganisira zvinonangwa uye zviratidzo zvine mwero wenjodzi mbiri.
GPC3 inovimbika yakanangana nemamota akasimba, kunyanya hepatocellular carcinoma, uko kudiwa kwekurapa kusingakwane kwakakosha. Cytovia's lead program ine chinangwa chekugadzira yekutanga-mu-kirasi HCC marapiro akanangana neGPC3. Iwo ekutanga echigadzirwa evamiriri vanozoongororwa se monotherapies uye semusanganiswa marapiro. CYT-303, Cytovia's GPC3 Flex-NK™ engager, inonzi tri-specific antibody inosunga kuHCC tumor cells kuburikidza neGPC3 uye kuNK masero kuburikidza neNKp46 uye CD16a. Kune varwere vane nhamba yakaremara kana basa reNK masero, Cytovia ichaongorora kuwedzerwa kweNK masero, CYT-100, kuti zvikwanise kuzarura mikana yakazara yeiyi nzira yekurapa. Cytovia iri kugadzirawo CYT-150, gene-edited inNK masero, kuvandudza bundu kupinza uye sero kuramba, izvo zvinogona zvakare kusanganiswa neCYT-303. Pamusoro pezvo, CYT-503, GPC3-yakananga CAR-iNK cell therapeutic, yakagadzirirwa kuvandudza hunhu hwekunangana nebundu. Cytovia inotarisira kuisa maIND eCYT-303 neCYT-100, ichiteverwa neINDs eCYT-150 neCYT-503.
CD38 inzvimbo yakasimbiswa yekiriniki uye yekutengesa yeMultiple Myeloma. Cytovia iri kugadzira CYT-338 uye CYT-538 izvo, zvichiteerana, CD38-targeting Flex-NK™ cell engagers uye CAR-iNK masero ekurapa Multiple Myeloma muvarwere vakakundikana CD38 antibody kurapa uye maajenti akanangana neB-cell maturation. Antigen (BCMA).
Cytovia iri kugadzirawo intracranial EGFR CAR iNK mumiriri kuti anange zvese wtEGFR neEGFR vIII kugadzirisa zvakakosha zvekurapa mukutonga kweiyo isingarapike Glioblastoma multiforme.
Cytovia yakagadzira kudyidzana nemasangano ezvidzidzo uye vashandi veindasitiri kusanganisira Cellectis yeTALEN® gene-editing. TALEN® gene-editing ndiyo tekinoroji yakapayona uye inodzorwa naCellectis, kambani yekiriniki-nhanho yebiotechnology inoshandisa puratifomu yekugadzira majini kugadzira kuponesa hupenyu hwesero nemishonga yemajini. TALEN® gene-edited patents inodzorwa neCellectis mundima yeNK neCAR-iNK inopihwa rezinesi kubva kuCellectis naCytovia uye Cytovia ine budiriro yepasi rose uye yekutengeserana kodzero kune aya matende.
Mamiriro Akarongwa uye Kushandiswa Kwemari
Mari inowanikwa kubva kune yakavanzika (iyo "PIPE"), mari muIsleworth's trust account (net of redemptions), uye inobuda kubva kune dzimwe inotarisirwa mari, muhuwandu hunosvika zana remamiriyoni emadhora, yaizopa Cytovia mari inosvika 2. makore ekuenderera mberi nekuvandudza gene-yakagadziriswa iNK uye Flex-NK™ cell engager tekinoroji. Cytovia inoronga kutarisa pane akati wandei mamiriro, kusanganisira:
• Kuisa maIND ekutanga eFlex-NK™ CYT-303 uye iNK CYT-100
• Kutanga Phase I/II miedzo yekiriniki yekuongorora CYT-303 uye CYT-100, yoga uye pamwe chete, yekurapa HCC.
• Kuwana nekupa ruzivo rwekutanga rwekiriniki rweCYT-303 neCYT-100 muHCC
• Kuisa IND dzeCYT-150 neCYT-503 uye kutanga Phase I/II miedzo yekiriniki
• Kuenderera mberi nekunatsiridza matekinoroji eNK & Flex-NK™ uye kufambisira mberi pombi nevanorapa vakawanda.
